Xenon Pharmaceuticals Inc. - Common Stock (XENE)

Q2 2024 13F Holders as of 30 Jun 2024

Type / Class
Equity / Common Stock
Shares outstanding
77,331,078
Total 13F shares
74,159,245
Share change
+770,931
Total reported value
$2,891,332,046
Put/Call ratio
102%
Price per share
$38.99
Number of holders
211
Value change
+$26,539,830
Number of buys
96
Number of sells
97

Institutional Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) as of Q2 2024

As of 30 Jun 2024, Xenon Pharmaceuticals Inc. - Common Stock (XENE) was held by 211 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 74,159,245 shares. The largest 10 holders included FMR LLC, Avoro Capital Advisors LLC, Driehaus Capital Management LLC, WELLINGTON MANAGEMENT GROUP LLP, COMMODORE CAPITAL LP, Capital World Investors, BRAIDWELL LP, Polar Capital Holdings Plc, Capital International Investors, and BlackRock Inc.. This page lists 212 institutional shareholders reporting positions in this security for the Q2 2024 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.